Treatment of Uncontrolled Hypertension with Microalbuminuria

Introduction to Treatment Approach

The American College of Cardiology and the American Diabetes Association recommend initiating an ACE inhibitor or ARB immediately at maximum tolerated doses, targeting blood pressure <130/80 mmHg, for patients with microalbuminuria (ACR 30-299 mg/g) indicating early kidney damage, as this provides both blood pressure control and renal protection 1, 2, 3

Patients with an ACR of 30-299 mg/g are considered to have microalbuminuria, representing early kidney damage and significantly elevated cardiovascular risk, according to the American Diabetes Association 4, 2
The American Diabetes Association suggests confirming microalbuminuria by obtaining two additional ACR measurements over 3-6 months, as transient elevations can occur with exercise, fever, marked hyperglycemia, urinary tract infection, or acute illness 4

The American Heart Association recommends starting with an ACE inhibitor (preferred) or ARB if ACE inhibitor is not tolerated, titrating to maximum tolerated doses indicated for blood pressure treatment, as these agents provide renal protection beyond blood pressure lowering alone 1, 2, 3
For patients with ACR 30-299 mg/g (microalbuminuria), ACE inhibitors or ARBs are reasonable (Class IIa recommendation); for ACR ≥300 mg/g, they are strongly recommended (Class I), according to the American College of Cardiology 1, 2

The American College of Cardiology and the American Heart Association recommend targeting BP <130/80 mmHg based on current guidelines for patients with hypertension and kidney involvement, as this lower target is critical because both systolic and diastolic hypertension accelerate progression of kidney damage 1, 2, 5

The American Diabetes Association suggests adding a thiazide-like diuretic (chlorthalidone or indapamide preferred over hydrochlorothiazide due to superior cardiovascular outcomes) if BP ≥140/90 mmHg on ACE Inhibitor/ARB alone 2, 3
The American Heart Association recommends adding a dihydropyridine calcium channel blocker (amlodipine, nifedipine) if BP ≥140/90 mmHg on ACE Inhibitor/ARB alone 2, 3

The American Diabetes Association recommends monitoring serum creatinine and potassium within 3 months of starting RAAS blockade to detect hyperkalemia or acute kidney injury, and annually thereafter 2, 5
The American College of Cardiology suggests monitoring blood pressure at every visit until controlled, then periodically, and annual ACR measurements to assess treatment response 2, 4, 6

The American Heart Association recommends adding a mineralocorticoid receptor antagonist (spironolactone or eplerenone) if BP remains ≥140/90 mmHg despite ACE inhibitor/ARB + thiazide-like diuretic + dihydropyridine CCB, as this provides additional antialbuminuric effects 2, 3

The American Heart Association recommends sodium restriction to 1,200-2,300 mg/day, weight loss if overweight/obese, DASH diet pattern with increased fruits, vegetables, and low-fat dairy, aerobic exercise ≥150 minutes/week, and alcohol limitation (≤1 drink/day for women, ≤2 drinks/day for men) while initiating pharmacotherapy 5

The American Diabetes Association suggests that if the patient has diabetes, the same approach applies, but ACE inhibitor/ARB becomes even more critical, and target HbA1c <7% as glycemic control also reduces albuminuria progression 6, 2, 4
The American College of Cardiology recommends that if the patient is female of childbearing age, ACE inhibitors and ARBs are contraindicated in pregnancy (Class C/D), and reliable contraception or alternative agents should be considered if pregnancy is planned 4, 6